Four Israeli cos expect FDA approvals in 2023

Treatments for blood cancer and rare diseases are the target markets, but investors are well aware of the challenges that await after approval is received.

Related Keywords

Italy ,Jerusalem ,Israel General ,Israel ,Karmiel ,Ha Afon ,Tel Aviv ,Italian ,Israeli ,Abigail Jenkins ,Dror Bashan ,Alpha Galactosidase ,Genzyme Sanofi ,Ofer Gonen ,Philip Serlin ,Amicus Therapeutics ,York Stock Exchange ,Drug Administration ,Nasdaq ,Pfizer ,Clal Biotechnology Industries ,New York Stock Exchange ,Tel Aviv Stock Exchange ,Teva Pharmaceutical Industries ,Pharmaceutical Industries ,Redhill Biopharma ,Purple Biotech ,Urogen Pharma ,Gamida Cell ,Fabry Disease ,Gaucher Disease ,